Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Jan-Feb;116(1):32-3.

[Therapy of primary open-angle glaucoma by oftan-dipivefrin]

[Article in Russian]
  • PMID: 10741262
Clinical Trial

[Therapy of primary open-angle glaucoma by oftan-dipivefrin]

[Article in Russian]
E A Egorov et al. Vestn Oftalmol. 2000 Jan-Feb.

Abstract

Choice of optimal hypotensive therapy with the minimal side effects remains a serious problem in therapy of glaucoma. The efficacy and safety of oftan-dipivefrin (Sante, Finland) and glaucon (Alcon, USA) are compared in a controlled balanced randomized open parallel study preceded by a period for discharge of the previous drugs. The period of discharge was 7 days, active treatment was administered for 8 weeks. Sixty patients aged 61-69 years were treated. Thirty-one patients were treated by oftan-dipivefrin (group 1) and 29 by glaucon (group 2). In parallel with this, a 1% pilocarpin solution was administered in both groups. The examinations carried out during all consultations included measurements of intraocular pressure before instillations every day at the same time, evaluation of visual acuity, tonography, and study of the central and peripheral visual fields. The time course of hypotensive effects of both drugs showed a sufficient decrease in intraocular pressure in both groups; the effect of oftan-dipivefrin was more pronounced, while glaucon caused the least number of side effects.

PubMed Disclaimer

MeSH terms